Receive a clinical evaluation by a board-certified provider for acne — tretinoin, clindamycin, doxycycline, spironolactone. Treatment may include medical advice, prescriptions (when appropriate), or referral for in-person care. Evidence-based AAD guidelines.

Board-Certified HIPAA-Compliant Same-Day Available DE · MD · WA

Book a Same-Day Visit →

Understanding Acne Vulgaris — Pathophysiology & Grading

Acne vulgaris is a multifactorial chronic inflammatory disorder of the pilosebaceous unit affecting an estimated 50 million Americans annually. The pathophysiology involves four key mechanisms: follicular hyperkeratinization (abnormal shedding of skin cells that plug the follicle), excess sebum production (driven by androgens), colonization and proliferation of Cutibacterium acnes (formerly Propionibacterium acnes), and the resulting inflammatory cascade. Understanding which of these mechanisms predominates in a given patient guides targeted treatment selection.

Acne lesions are classified as non-inflammatory (comedonal) or inflammatory. Comedones are plugged follicles: open comedones are blackheads (oxidized keratin plug), closed comedones are whiteheads. Inflammatory lesions include papules (solid raised lesions under 5mm), pustules (pus-containing lesions), nodules (deep, firm lesions over 5mm), and cysts (fluctuant, deep lesions prone to scarring). Severity grading ranges from mild (primarily comedonal or few inflammatory lesions) to moderate (multiple inflammatory papules and pustules) to severe (nodular/cystic acne covering large areas). Accurate grading by your board-certified provider, guides stepwise treatment selection aligned with AAD acne guidelines.

Acne disproportionately affects the face, chest, and back — the sebaceous gland-dense areas. Hormonal acne in adult women often presents as deep, painful, predominantly jawline and chin lesions that flare perimenstrually, reflecting androgen-driven seborrhea. This pattern responds well to anti-androgen therapies such as spironolactone and oral contraceptives in addition to conventional topical regimens. Accurate pattern recognition via photo and video assessment is central to Innocre's acne evaluation process.

Acne Treatments Available Online

Evidence-Based Acne Care — AAD Guidelines & Isotretinoin Note

The American Academy of Dermatology (AAD) 2016 acne clinical guidelines — updated with supplements through 2024 — form the evidence backbone for acne management at Innocre. The guidelines recommend topical retinoids as the cornerstone of most acne treatment regimens due to their ability to prevent and clear both comedonal and inflammatory lesions. Benzoyl peroxide is recommended in all antibiotic-containing regimens to prevent the emergence of antibiotic-resistant C. acnes. Oral antibiotics are time-limited therapies (typically 3–6 months) always used in combination with topical agents — never as monotherapy. your provider's prescribing practices reflect these evidence-based principles.

For women with hormonal acne patterns — typically adult women with deep, painful, cyclical breakouts along the jaw and chin — spironolactone is a highly effective off-label but guideline-supported option. Starting at 25–50mg daily and titrating up to 100–200mg as tolerated, spironolactone reduces sebum production by blocking androgen receptors. Potassium monitoring and blood pressure checks are appropriate for higher doses. Combined oral contraceptive pills with low androgenic progestins are also effective and FDA-approved for acne. These options are available via telehealth for appropriate candidates.

Isotretinoin (Accutane) is the most effective treatment for severe nodular/cystic acne and acne resistant to other therapies, but it cannot be prescribed via telehealth. Isotretinoin requires enrollment in the FDA's iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program — mandatory monthly labs, in-person pregnancy tests for women of childbearing potential, and monthly in-person visits for the duration of treatment. Patients with severe acne, significant scarring, or acne unresponsive to multiple other treatments will receive a referral to an in-person dermatologist for isotretinoin evaluation.